June 12th 2024
The decision is based on statistical significance achieved in the T2NOW trial, which demonstrated reduction of A1C.
FDA approves teplizumab for delay of type 1 diabetes in patients 8 years and up
November 18th 2022The US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.
Study finds children, young adults with down syndrome more likely to develop diabetes
October 17th 2022An analysis of data from more than 9900 people with Down syndrome and 38,000 controls provides new insight into the apparent increase in risk of developing diabetes among children and young adults with Down syndrome.
How changes in diet can manage gestational diabetes
October 3rd 2022In a recent presentation the NPWH 25th Annual Premier Women's Healthcare Conference, Jenny Madrid, MPH, RD, CDCES, BC-ADM, discussed medical nutrition therapy, a type of treatment plan for managing gestational diabetes by adjusting to an appropriate diet.
In gestational diabetes, tighter glycemic targets could influence outcomes for mother and child
September 23rd 2022Results of the TARGET trial provide insight into the effects of tight glycemic targets versus less tight targets on maternal and perinatal outcomes among women with gestational diabetes.
Available Therapies for the Management of Severe Hypoglycemia in Pediatric Patients with Diabetes
September 12th 2022Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDCES reviews the currently available rescue modalities for use in pediatric patients with diabetes experiencing severe hypoglycemia or very low blood sugar.